Abstract
The Philadelphia (Ph)-like Acute Lymphoblastic Leukemia (ALL) is a recently described class of B-cell ALL, characterized by an expression pattern similar to the one observed in the t(9;22) positive subtype. ‘Ph-like’ leukemias are frequently resistant to standard chemotherapy and have a high probability of relapse; however, they were shown to respond to treatment with tyrosine kinase inhibitors (TKIs), since they are characterized by activated kinase signature. This study evaluated the utility of chromosomal microarray analysis (CMA) in detecting genetic abnormalities associated with Ph-like ALL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
